Advanced Refractory Solid Tumors Clinical Trial
Official title:
A Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of NOV120401 (CKD-516 Tablet) in Patients With Advanced Refractory Solid Tumors
The purpose of this open-label, dose-escalation phase I trial is to evaluate the safety, tolerability and pharmacokinetic profiles and to assess the efficacy of NOV120401 (CKD-516 Tablet), a novel vascular disrupting agent, in patients with advanced refractory solid tumors.
Vascular disrupting agents are expected to kill cancer cells located in core of tumor tissues by disrupting microvascular structure of tumor. To assess the safety and tolerability of NOV120401 (CKD-516 Tablet), patients with advanced refractory solid tumors will be enrolled in this study. Initial dose of NOV120401 (CKD-516 Tablet) is 5 mg/day, which will be escalated until at least 2 of 6 subjects show dose-limiting toxicities (DLTs). Pharmacokinetic profiles and efficacy by tumor response and vascular disrupting activities will also be assessed. ;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Suspended |
NCT01762410 -
Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors
|
Phase 1 | |
| Terminated |
NCT03195764 -
Safety and Tolerability Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT03349073 -
An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04892498 -
Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)
|
Phase 2 | |
| Recruiting |
NCT05035745 -
Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03863145 -
Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors
|
Early Phase 1 | |
| Active, not recruiting |
NCT04685473 -
Safety and Tolerability Study for T-1101 (Tosylate) Capsules to Treat Advanced Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT04324372 -
Clinical Study of HEC68498 in Patients With Advanced Refractory Solid Tumors
|
Phase 1 | |
| Suspended |
NCT01779336 -
Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT04200404 -
A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors
|
Phase 1/Phase 2 |